{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:57:26Z","timestamp":1770062246588,"version":"3.49.0"},"reference-count":13,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The first\u2010generation BTK inhibitor ibrutinib is a standard\u2010of\u2010care therapy in the treatment of chronic lymphocytic leukemia (CLL) despite potential side effects that often lead to discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study used 2013\u20132019 claims data to describe the incidence rate of adverse events (AEs) among elderly Medicare beneficiaries newly initiating ibrutinib for CLL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The final sample contained 11,870 Medicare beneficiaries with CLL (mean age 77.2) newly initiating ibrutinib, of whom 65.2% discontinued over mean follow\u2010up of 2.3\u2009years. The overall incidence rate of AEs was 62.5 per 1000 patient\u2010months for all discontinuers and 32.9 per 1000 patient\u2010months for non\u2010discontinuers. Discontinuers had a higher incidence rate of AEs per 1000 patient\u2010months compared with non\u2010discontinuers for all AEs examined, including infection (22.8 vs. 14.5), atrial fibrillation (15.1 vs. 7.0), anemia (21.9 vs. 14.5), and arthralgia\/myalgia (19.5 vs. 13.6).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this first real\u2010world study of a national sample of elderly US patients treated with ibrutinib, we found a clear unmet need for improved management of ibrutinib\u2010related AEs and\/or new treatments to improve real\u2010world outcomes in patients with CLL.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.6953","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T12:18:44Z","timestamp":1706789924000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real\u2010world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6475","authenticated-orcid":false,"given":"Scott F.","family":"Huntington","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology Yale University School of Medicine  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"de Nigris","sequence":"additional","affiliation":[{"name":"MSD (UK) Limited  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5135-7216","authenticated-orcid":false,"given":"Justin T.","family":"Puckett","sequence":"additional","affiliation":[{"name":"COVIA Health Solutions  Ambler Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Kamal\u2010Bahl","sequence":"additional","affiliation":[{"name":"COVIA Health Solutions  Ambler Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Ryland","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Sarpong","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyang","family":"Leng","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Yang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalpa A.","family":"Doshi","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Perelman School of Medicine University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24826"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25436"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014960"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-716977"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00870-w"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16922"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112679"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1602268"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.06.004"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007938"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00512-0"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.6953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T06:35:01Z","timestamp":1709534101000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.6953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/cam4.6953"],"URL":"https:\/\/doi.org\/10.1002\/cam4.6953","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e6953"}}